Rilparencel

N/A

Report date: 2025/09/22 17:47:49

Base Information

Drug NameRilparencel
Drug Alias NameAutologous cultured kidney tissue cells (Tengion)Autologous Neo-Kidney augmentNeo-Kidney AugmentNeo-kidney-augmentRegenerative autologous cell therapy +[10] 
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Renal epithelial cell therapyCell and gene therapy > Cell therapy > Source of cells > Renal cortexl tissue-derivedCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Renal Insufficiency, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesProKidney LLCRegenmedtx
China Registration ClassN/A

Develop Information

Active CompaniesProKidney LLC
Inactive CompaniesTengion Inc
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Renal Insufficiency, Chronic
Inactive IndicationsDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A